Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions
, , , , , , y
13 jul 2022
Acerca de este artículo
Publicado en línea: 13 jul 2022
Páginas: 135 - 143
DOI: https://doi.org/10.2478/prilozi-2022-0026
Palabras clave
© 2022 Emilija Atanasovska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Atanasovska, Emilija
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Jakjovski, Krume
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Pavlovska, Kristina
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Gjorgjievska, Kalina
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Zafirov, Dimche
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Zendelovska, Dragica
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Petrushevska, Marija
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia
Labachevski, Nikola
Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University “Ss. Cyril and Methodius”Skopje, Republic of North Macedonia